Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.

Authors :: Ernst, Sophie M.
Uzun, Sevim
Paats, Marthe S.
van Marion, Ronald
Atmodimedjo, Peggy N.
de Jonge, Evert
van Schaik, Ron H.N.
Aerts, Joachim G.J.V.
von der Thüsen, Jan H.
Dubbink, Hendrikus J.
Dingemans, Anne-Marie C.
Source :: JCO Precision Oncology. 12/14/2023, Vol. 7, p1-5. 5p.
Publication Year :: 2023
Abstract: Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance. [ABSTRACT FROM AUTHOR]

Full Text Access

Tools